Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 7/20 | 0.42 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13578195 | 0.94 | CNR1 (0.45) | RORCHTR4CNR1CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4325507 | 0.91 | MAP2K3 (0.50) | RORCHTR4CNR1CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4339713 | 0.88 | CSNK1D (0.46) | RORCHTR4CNR1PPARG | |
| Trifluoroacetic Acid SCHEMBL4329769 | 0.86 | ATM (0.44) | RORCHTR4CNR1CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4336494 | 0.86 | RORC (0.44) | RORCHTR4CNR1PPARGMAP2K3 | |
| SCHEMBL13578149 | 0.85 | MAP2K3 (0.56) | HTR4CNR1CYP3A4CYP2D6MAP2K3 | |
| Trifluoroacetic Acid SCHEMBL4326422 | 0.84 | L3MBTL1 (0.42) | RORCHTR4PPARGMAP2K3 | |
| Trifluoroacetic Acid SCHEMBL4325959 | 0.84 | HTR4 (0.43) | HTR4CNR1CYP3A4CYP2D6CNR2 | |
| Trifluoroacetic Acid SCHEMBL4331249 | 0.83 | GABRA5 (0.40) | RORCHTR4CNR1CYP3A4CYP2D6 | |
| SCHEMBL4324377 | 0.83 | MAP2K3 (0.44) | RORCHTR4CNR1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | RORC 135/4885HTR4 254/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.